EndoTODAY | EndoATLAS | ¿Ü·¡¼³¸íÀÚ·á

±â»ýÃæ | ½Äµµ | À§ | À§¾Ï | ESD | õ±â´©¼³

Home | Guide | ÁÖÀÎÀå | ±¸µ¶ | °Ë»ö | ¸µÅ©


[Asian Young Endoscopist Forum]

½Ã°£: 2016³â 6¿ù 24ÀÏ ¿ÀÈÄ

Àå¼Ò: ±×·£µå ÈúÆ° È£ÅÚ

¾Æ½Ã¾Æ °¢±¹ÀÇ ÀþÀº ÀÇ»çµéÀÌ ¿ì¸®³ª¶ó ¿©·¯º´¿ø¿¡¼­ 2ÁÖ°£ÀÇ trainingÀ» ¹Þ´Â ÇÁ·Î±×·¥À̾ú½À´Ï´Ù. °¢ÀÚ ÂªÀº presentationÀ» ÇÏ¿´½À´Ï´Ù. Àú´Â ù¹ø° ¼¼¼ÇÀÇ discussant·Î Âü¿©ÇÏ¿´½À´Ï´Ù. Èï¹Ì·Î¿ü´ø ¹ßÇ¥ ¸î °³¸¦ ¿ä¾àÇÕ´Ï´Ù.


1. The use of self-expanding metal stent for refractory variceal haemorrhage. Chinmay Bera (India)

ÁÖ·Î EVL ÈÄ ¹ß»ýÇÑ EVL ulcer·Î ÀÎÇÑ refractory esophageal bleedingÀ» self-expandable esophageal covered metal stent (SX-Ella DANIS stent, Czech Republic)·Î Ä¡·áÇÑ °æÇèÀ» ¹ßÇ¥ÇÏ¿´½À´Ï´Ù.

¸¶Ä§ °°Àº stent Á¦Ç°À» »ç¿ëÇÑ ¿¬±¸°¡ 2016³â 6¿ù HepatologyÁö¿¡ ¹ßÇ¥µÇ¾ú½À´Ï´Ù (Escorsell A. Hepatology 2016).

Results: Twenty-eight patients were randomized to Sengstaken-Blakemore tube (n = 15) or SX-ELLA Danis stent (n=13). Patients were comparable in severity of liver failure, active bleeding at endoscopy, and initial therapy. Success of therapy was more frequent in the esophageal stent than in balloon tamponade group (66% vs. 20%; P=0.025). Moreover, control of bleeding was higher (85% vs. 47%; P=0.037) and transfusional requirements (2 vs 6 PRBC; P=0.08) and SAEs lower (15% vs. 47%; P=0.077) in the esophageal stent group. TIPS was used more frequently in the tamponade group (4 vs. 10; P=0.12). There were no significant differences in 6-week survival (54% vs. 40%; P = 0.46).

Hepatology¿¡ ½Ç¸° ÀÛÀº ±Ô¸ðÀÇ ¿¬±¸¿´Áö¸¸ °á°ú´Â ÀλóÀûÀÔ´Ï´Ù. Refractory variceal bleedingÀº ¸Å¿ì ÇèÇÑ »óȲÀÔ´Ï´Ù. Survival graphÀÇ dimensionÀÌ 6ÁÖ¿´½À´Ï´Ù. 6 week survival rate!!!

³í¹®ÀÇ discussion¿¡¼­ ÀϺθ¦ ¿Å±é´Ï´Ù. "These better results are owing to both a greater hemostatic effect and a lower rate of SAE, especially of aspiration pneumonia, with the use of esophageal stents. Because esophageal stents can be left safely in place for over 5 days, this procedure would be specially valuable for centers with-out facilities for early TIPS." TIPS¸¦ »¡¸® ÇÒ ¼ö ÀÖ´Ù¸é Áï½Ã TIPS¸¦ ½ÃÇàÇÏ´Â °ÍÀº ¾î¶²°¡ »ý°¢ÇØ º¸¾Ò½À´Ï´Ù.

* Âü°í: EndoTODAY Á¤¸Æ·ù Ä¡·á (°­¿ø¼® ±³¼ö´Ô °­ÀÇ)


2. GIST presenting as gastroduodenal intussuscption (Eric Yasay, Philippines)

Dr. Yasay ¹ßÇ¥¿Í ºñ½ÁÇÑ Áõ·Ê¸¦ Àú³Î¿¡¼­ ã¾Ò½À´Ï´Ù (Yildiz. J Gastric Cancer 2016).

(A) Gastroduedonal intussusception. (B, C) The mass protruding to the duedonum and causing obstruction (arrows). Also visible are stranding of the peripancreatic fat and fluid accumulation around heterogenously ehancing pancreas, a sign of early necrosis. (D) Macroscopic view of the mass arising from gastric corpus (arrow). (E) Perioperative view of pancreas. Please note relatively dark portion of the pankreas corresponding to pancreatic necrosis.


3. Structured enteroscopy and capsule endoscopy training workshop enhanced skills and understanding of trainees

Methods: The workshop was a two day even held on June 2015. The program consisted of lectures, computer workstation for capsule endoscopy (CE), ex vivo models for single balloon enteroscopy (SBE) hands-on, and an interactive live demonstration with SBE. A twenty item multiple-choice written eam was administered before and after the lectures.

ÀÌƲ µ¿¾È ¿­½ÉÈ÷ °¡¸£ÃÆ´õ´Ï ¾öû ÁÁ¾ÆÁ³´Ù´Â °á°ú¿´½À´Ï´Ù. Webpage¸¦ ÀÌ¿ëÇÏ¿© Áö¼ÓÀûÀÎ ±³À°µµ ÇÔ²² ÁøÇàÇÏ°í ÀÖ´Ù°í ÇÕ´Ï´Ù. Àؾî¹ö¸®Áö ¸»¶ó°í...


4. A single center audit of sphincter of Oddi dysfunction managed by ERCP under propofol deep sedation. Shqan Karim (New Zealand)

Conclusion: SOD remains a challenging condition to treat needing recurrent procedures. High risk of management with ERCP, however our data shows low risk of pancreatitis in setting of well selected patients treated under propofol sedation by a skilled endoscopist.

´ºÁú·£µå¿¡¼­ propofolÀº ¸¶Ãë°ú Àǻ縸 Åõ¿©ÇÒ ¼ö ÀÖ´Ù°í ÇÕ´Ï´Ù. ¹°·Ð »ó´çÇÑ ºñ¿ëÀÌ ¹ß»ýÇÑ´Ù°í Çϳ׿ä. ÀϹÝÀûÀÎ »óºÎ³»½Ã°æÀ̳ª ´ëÀå³»½Ã°æÀº midazolam sedation¸¸ »ç¿ëÇÏ°í ÀÖ´Ù°í ÇÏ´Ï ¿ì¸®µµ Âü°íÇÒ ÇÊ¿ä°¡ ÀÖ°Ú½À´Ï´Ù. PropofolÀº ¸Å¿ì ¹«Ã´ ´ë´ÜÈ÷ ¾öû ³î¶ö¸¸Å­ ¹«¼­¿î ¾àÀ̴ϱî¿ä.

* Âü°í: EndoTODAY ³»½Ã°æ ÁøÁ¤


5. Building a mentorship: Being a good mentor / Finding a good mentor. (William R. Brugge, Harvard Medical School, USA)

Don't put blinders on. Keep your eyes open

Indentify important questions. Focus on field. Write proposals. Build a mentorship. Write manuscript. Give talks and seminars. Teach

Learn early: statistics, size calculation, data testing

Don't search for answers; create answers

Consider global health issues. Big questions.

Think about the most important questions that are unanswered in the field.

Find a question or a problem that excites or drives you.

Don't be afraid. Get out of the silo of your own community and field.

Stay up to date on journal reading.

Prioritize. Plan ahead!! Do NOT tackle everything at once.


[Âü°í ÀÚ·á]

1) ³»½Ã°æÇÐȸ ÇмúÇà»ç on-line Áß°è

© ÀÏ¿ø³»½Ã°æ±³½Ç ¹Ù¸¥³»½Ã°æ¿¬±¸¼Ò ÀÌÁØÇà